Verrica Pharmaceuticals Inc.
NASDAQ:VRCABiotechnology
-$0.02 today
- Market cap
- $53.94M
- Beta
- 1.49
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$1.67
Volume 0.10M
Average 0.08M
Returns on capital
Verrica Pharmaceuticals Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-72.3%
avg 12.7%
ROIC
-38.0%
avg -211.2%
ROA
-37.9%
avg -88.6%
Analysis
ROA is currently the strongest return metric at -37.9% versus its period average of -88.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Chris Chapman | Chief Commercial Officer | USD 635.38K | — | — | — |
John J. Kirby | Interim Chief Financial Officer | USD 532.5K | 54 | 23.96K | 0.22% |
Jayson Rieger | President, Chief Executive Officer & Director | USD 391.17K | 50 | 207.59K | 1.95% |
Noah L. Rosenberg | Chief Medical Officer | USD 243.32K | 59 | 8.59K | 0.08% |
Bradley J. Catalone | Head of Drug Development | — | — | — | — |
David Zawitz | COO, Chief Legal Officer & Secretary | — | 45 | 27.00K | 0.25% |
Eugene Scavola | Executive Vice President of Technical Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 18, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
18
$24.87M
Sells
0
$0.00
Net Transaction Value
+$24.87M
Net buying
Most Active
Rosenberg Noah L.
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 18, 26Aug 18, 2026 | Rosenberg Noah L. Direct | Buy | $10K$9,987.60 |
| Aug 18, 26Aug 18, 2026 | Kirby John J. Direct | Buy | $24.7K$24,650.00 |
| Aug 17, 26Aug 17, 2026 | Zawitz David Direct | Buy | $29.9K$29,880.00 |
| Aug 17, 26Aug 17, 2026 | Rosenberg Noah L. Direct | Buy | $20.6K$20,622.00 |
| Aug 17, 26Aug 17, 2026 | Rieger Jayson Direct | Buy | $24.6K$24,550.00 |
| Aug 14, 26Aug 14, 2026 | Rieger Jayson Direct | Buy | $101.2K$101,200.00 |
| Nov 25, 25Nov 25, 2025 | Rosenberg Noah L. Direct | Buy | $10K$9,999.57 |
| Nov 25, 25Nov 25, 2025 | Rosenberg Noah L. Direct | Buy | $3.7K$3,719.54 |
| Nov 25, 25Nov 25, 2025 | Kirby John J. Direct | Buy | $15K$15,001.48 |
| Nov 25, 25Nov 25, 2025 | Kirby John J. Direct | Buy | $5.6K$5,582.46 |
1–10 of 18
Summary
Insiders reported 18 buys worth $24.87M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $24.87M. Rosenberg Noah L. was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +57.9% | +14.5% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +57.9% over three years. Forward estimates point to Revenue at +14.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Verrica Pharmaceuticals Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about VRCA's management, answered from reported figures.
Who manages VRCA?
Verrica Pharmaceuticals Inc. (VRCA) lists 7 active executives. The top listed executive is Bradley J. Catalone, Head of Drug Development.
Are VRCA insiders buying or selling?
Recent insider activity shows net buying of $147.14M.
Continue the stock analysis
Jump to another research area for this company.